Kapanta DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to provide symptomatic relief in gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, acts as a prokinetic agent by enhancing gastric motility and accelerating gastric emptying, thereby reducing symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, effectively reducing gastric acidity and promoting healing of acid-related mucosal damage. The combined action of Domperidone and Pantoprazole makes Kapanta DSR Capsule suitable for the management of gastroesophageal reflux disease (GERD), peptic ulcer disease, and other acid-peptic disorders accompanied by motility disturbances. It is generally well tolerated when administered as prescribed, but caution is advised in patients with known hypersensitivity to either component, cardiac arrhythmias, or severe hepatic impairment. Kapanta DSR Capsule should be used under medical supervision, with dosage adjustments based on clinical response and patient-specific factors. This combination therapy offers a comprehensive approach to managing symptoms related to acid secretion and impaired gastric motility.